Jerusalem [Israel], December 22 (ANI/TPS): Netanya-based biotechnology startup BioGenCell announced it has received the US Food and Drug Administration's Fast Track Designation for BGC101, a personalized cell therapy for severe Critical Limb Threatening Ischemia (CLTI).
CLTI is a life-threatening form of peripheral artery disease, usually occurring in the legs.
Using its TRACT platform, BGC101 regenerates damaged tissue, offering hope to patients with no other treatment options. The milestone follows promising clinical results. BioGenCell recently completed Phase 2 trial enrollment across the US, Europe, and Israel. (ANI/TPS)
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor